BETA
BETA DRUGS LIMITED
Each stock's 10,000-path forecast, rendered as light.
BETA DRUGS LIMITED (BETA) Stock Analysis & Case Study
Is BETA a good buy? The data-driven verdict.
BETA DRUGS LIMITED (BETA) trades at ₹2,374,on the numbers it mixed signals, a Downstox Snapshot Score of 47/100.
On the numbers, BETA DRUGS LIMITED (BETA) mixed signals, a Downstox Snapshot Score of 47/100, weighing expensive at 57.7× earnings, ROE of 18.8%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
BETA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How BETA ranks against the 2,373 companies in our screener
- BETA's market cap of 2,631 Cr ranks in the 55th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's book value of ₹241 ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's promoter holding of 59.1% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's 3-year profit (PAT) growth of 11.0% ranks in the 43rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's 3-year revenue growth of 19.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's debt-to-equity ratio of 0.60x is lower than 30% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is BETA overvalued? BETA P/E vs peers
BETA trades at 57.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
BETA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 8.6y of BETA history (36%/yr drift, 51%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| BETA 2027 | ₹1,221 | ₹2,395 | ₹4,699 | +1% |
| BETA 2028 | ₹943 | ₹2,416 | ₹6,190 | +2% |
| BETA 2029 | ₹763 | ₹2,438 | ₹7,787 | +3% |
| BETA 2030 | ₹643 | ₹2,460 | ₹9,408 | +4% |
| BETA 2031 | ₹556 | ₹2,482 | ₹11,076 | +5% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability BETA goes up, or doubles?
The bull case for BETA
- BETA's return on equity of 18.8% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- BETA's return on capital employed of 19.2% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹7,787.
The bear case & risks
- BETA's P/E of 57.7x is lower than 22% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 9.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹763.
BETA volatility & expected range, how bumpy is the ride?
Over the last 8.6 years BETA compounded at 36%/year with annualized volatility of 51%. That volatility implies a 1-year 80% range of ₹1,221-₹4,699, the honest backbone behind any single price target.
BETA price forecast, the full 60-month probability fan
BETA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds BETA hits common targets within the simulated horizon?
Full multi-horizon detail on the BETA price target & forecast page.
BETA Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. BETA scores 5/8, mixed financial health.
BETA MTF margin & leverage across 7 brokers
Margin Trading Facility lets you buy BETA with part of the capital. Lower margin % = higher leverage. Rates compared across 7 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 37.53% | 2.7× |
| Zerodha | 50.00% | 2.0× |
| Dhan | 50.00% | 2.0× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 37.53% | 2.7× |
| Pocketful | 50.00% | 2.0× |
| Share IndiaCHEAPEST | 37.46% | 2.7× |
Compare every broker on the BETA MTF page.
About BETA DRUGS LIMITED: sector, index & market-cap context
BETA DRUGS LIMITED (BETA) is a small-cap NSE-listed company, with a market capitalisation of ₹2,631 Cr. See more stocks on our screener.
How the BETA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of BETA DRUGS LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
BETA analysis, FAQs
Is BETA DRUGS LIMITED (BETA) a good buy?
On the numbers, BETA DRUGS LIMITED (BETA) mixed signals, a Downstox Snapshot Score of 47/100, weighing expensive at 57.7× earnings, ROE of 18.8%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is BETA overvalued or undervalued?
BETA trades at 57.7× earnings, expensive versus the ~22× long-run Nifty average.
What is the BETA share price target for 2031?
BETA's probability-weighted 2031 median target is ₹2,482, with an 80% range of ₹556-₹11,076 (10,000-path Monte-Carlo).
What is the probability BETA doubles in 5 years?
The modelled probability of BETA reaching ₹4,747 (2×) within 5 years is 29%.
What is the bull case for BETA?
BETA's return on equity of 18.8% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. BETA's return on capital employed of 19.2% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in BETA?
BETA's P/E of 57.7x is lower than 22% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 9.8× price-to-book means most of the value is intangible/expectations, not assets on the books. High historical volatility (51%/yr) means a wide, bumpy range of outcomes, size positions accordingly.